Supply Chain
Long wait times, crowded waiting rooms, and frustrated staff are often symptoms of inefficient workflows driven by physical space constraints.…
On Thursday, Sen. Bernie Sanders (I-Vt.) and Rep. Elijah Cummings (D-Md.) called on federal antitrust regulators to investigate the pricing practices of Sanofi, Eli Lilly, Merck and Novo Nordisk, alleging the drugmakers all intentionally set high prices for insulin and…
Mountain View, Calif.-based Omnicell recently launched an integrated services and software program to help improve pharmacy operations through long term face-to-face relationships with its customers.
Seconds after Chicago Cubs third baseman Kris Bryant tossed the ball to first base — donning a huge grin on his face — to make the final out of the 2016 World Series, factory workers started heat-sealing embroidered Cubs' logo…
Flagstaff-based Northern Arizona Healthcare Partners and Charlotte, N.C.-based healthcare improvement company Premier are partnering to improve efficiency in NAHP's purchasing program.
The Food and Drug Administration has a retention problem, primarily because it can't keep up with competitive offers from pharmaceutical companies.
As part of a larger effort to liquidate its assets and eliminate debt, Valeant Pharmaceuticals is considering a sale of its eye-surgery equipment business, reported The Wall Street Journal.
San Francisco-based Prologis — the largest warehouse owner in the world — plans to build a three-story, 580,000-square-foot warehouse outside of downtown Seattle, reported The Wall Street Journal.
The northern Mexican border has seen a steep decline in factory and warehouse leases amid growing concerns about how the outcome of the U.S. presidential election will affect the manufacturing industry, reported The Wall Street Journal.
Pfizer pulled the plug on the development of a cholesterol-lowering drug called bococizumab, citing a lack of commercial potential, reports Bloomberg Gadfly.
While many drug investors are growing nervous about the upcoming election, the most recent earnings season conjures up new concerns for the pharmaceutical industry in regard to the slowdown in sales of key blockbuster drugs, reported The Wall Street Journal.